Scarica l'app Stockscreener
4.30
5.13%
0.21
Pre-mercato:
4.41
0.11
+2.56%
Aardvark Therapeutics Inc Borsa (AARD) Ultime notizie
[EFFECT] Aardvark Therapeutics, Inc. SEC Filing - Stock Titan
Aardvark Therapeutics (AARD) price target decreased by 43.62% to 18.77 - MSN
Aardvark ups to $150M ATM sale with Piper Sandler (NASDAQ: AARD) - Stock Titan
Aardvark Therapeutics, Inc. (AARD) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Aardvark Therapeutics, Inc. (AARD) Shareholders to Inquire about Securities Investigation - accessnewswire.com
AARD Forecast, Price Target & Analyst Ratings | AARDVARK THERAPEUTICS INC (NASDAQ:AARD) - ChartMill
Aardvark Therapeutics, Inc. (NASDAQ:AARD) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aardvark Therapeutics, Inc. (AARD) And Encourages Investors to Connect - accessnewswire.com
AARD Technical Analysis & Stock Price Forecast - Intellectia AI
Why Aardvark Therapeutics (AARD) paused late-stage ARD-101 trials after cardiac findings - msn.com
Bronstein, Gewirtz & Grossman, LLC Encourages Aardvark Therapeutics, Inc. (AARD) Stockholders to Inquire about Securities Investigation - accessnewswire.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aardvark Therapeutics, Inc. (AARD) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Why Aardvark Therapeutics (AARD) Paused Late-Stage ARD-101 Trials After Cardiac Findings - Insider Monkey
Aardvark Therapeutics, Inc. (NASDAQ:AARD) Sees Significant Drop in Short Interest - MarketBeat
Why is Aardvark Therapeutics stock sinking Monday? - MSN
Aardvark Therapeutics, Inc. (AARD) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
US Stocks Recap: Does Aardvark Therapeutics Inc align with a passive investing strategyWeekly Risk Report & Risk Adjusted Swing Trade Ideas - baoquankhu1.vn
Heart activity changes prompted pause in trial of ARD-101 in PWS - Prader-Willi Syndrome News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc.AARD - PR Newswire
Decliners Report: Can Aardvark Therapeutics Inc outperform under higher oil prices2026 Fed Impact & Long-Term Safe Investment Plans - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aardvark Therapeutics, Inc. (AARD) And Encourages Stockholders to Connect - ACCESS Newswire
Jones Trading cuts Aardvark Therapeutics stock price target on trial delay - au.investing.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark ... - Bluefield Daily Telegraph
User - The Chronicle-Journal
Raymond James reiterates Aardvark Therapeutics stock rating on dosing path By Investing.com - Investing.com Australia
Raymond James reiterates Aardvark Therapeutics stock rating on dosing path - Investing.com
Aardvark Therapeutics, Inc. Files Form 8-K Announcing Entry Into Material Definitive Agreement – Company Details, Nasdaq Symbol AARD, and Contact Information - Minichart
Cantor Fitzgerald reiterates Aardvark Therapeutics stock rating By Investing.com - in.investing.com
AARD Stock Price and Chart — NASDAQ:AARD - TradingView
Cantor Fitzgerald reiterates Aardvark Therapeutics stock rating - investing.com
B.Riley cuts Aardvark Therapeutics stock price target on trial pause By Investing.com - Investing.com South Africa
BTIG Research Reaffirms Buy Rating for Aardvark Therapeutics (NASDAQ:AARD) - MarketBeat
Aardvark Therapeutics Inc. has officially signed an equity distribution agreement with Piper Sandler. - Bitget
Balancing Safety Concerns and Long-Term Opportunity: Justifying a Buy Rating on Aardvark Amid ARD-101 Clinical Risks - TipRanks
B.Riley cuts Aardvark Therapeutics stock price target on trial pause - Investing.com India
Aardvark Therapeutics Pauses Phase 3 Trials for ARD-101 in Prader-Willi Syndrome, Reports 2025 Financial Results and Pipeline Updates - Minichart
Aardvark Therapeutics Establishes $150 Million Equity Program - tipranks.com
Aardvark Therapeutics (NASDAQ: AARD) launches $150M at-the-market stock program - Stock Titan
Aardvark Therapeutics Launches $150 Million ATM Equity Program With Piper Sandler - TradingView
Aardvark Therapeutics, Inc. – Clinical-Stage Biopharma Advancing TAS2R Small-Molecule Therapies for Obesity and Metabolic Diseases - Minichart
Aardvark Therapeutics Files $400 Million Mixed Shelf - marketscreener.com
Aardvark Therapeutics (AARD) registers $400M shelf; $150M ATM included - Stock Titan
Aardvark Therapeutics reports fourth quarter and full year 2025 financial results and provides business updates - marketscreener.com
Aardvark Therapeutics 10-K: $0 Revenue; $(2.93) EPS - TradingView
Aardvark Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates - Bitget
Aardvark Therapeutics (AARD) halts ARD-101 PWS Phase 3 to probe cardiac signal - Stock Titan
AARD: Clinical trial pauses and strong cash reserves define the period, with guidance due in Q2 2026 - TradingView
Aardvark Therapeutics (NASDAQ: AARD) halts ARD-101 and ARD-201 trials as 2025 loss widens - Stock Titan
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):